AMPH
Amphastar Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$26.93
+2.28%Year over year
Reported trailing growth
- Revenue
- +1.4%
- EBITDA
- -22.9%
- EBIT
- -37.1%
- EPS
- -37.9%
- Free cash flow
- +36.3%
- Operating cash flow
- +15.6%
Forward estimates
Based on analyst estimates
- Revenue
- +7.1%
- EBITDA
- +39.8%
- EPS
- +85.1%
Three-year CAGR
- Revenue
- +13.0%
- EBITDA
- +13.3%
- EBIT
- +9.3%
- Net income
- +2.4%
- EPS
- +3.8%
- Free cash flow
- +23.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026